Skip header and navigation

Refine By

417 records – page 1 of 42.

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

https://arctichealth.org/en/permalink/ahliterature166939
Source
Drug Alcohol Depend. 2007 Apr 17;88(1):75-8
Publication Type
Article
Date
Apr-17-2007
Author
Hannu Alho
David Sinclair
Erkki Vuori
Antti Holopainen
Author Affiliation
National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland. hannu.alho@ktl.fi
Source
Drug Alcohol Depend. 2007 Apr 17;88(1):75-8
Date
Apr-17-2007
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Analgesics, Opioid - administration & dosage
Buprenorphine - administration & dosage - economics
Drug Combinations
Female
Finland - epidemiology
Humans
Male
Middle Aged
Naloxone - administration & dosage - economics
Narcotic Antagonists - administration & dosage
Opioid-Related Disorders - epidemiology
Self Medication
Substance Abuse, Intravenous - economics - epidemiology
Abstract
Buprenorphine (Subutex) is widely abused in Finland. A combination of buprenorphine plus naloxone (Suboxone) has been available since late 2004, permitting a comparison of the abuse of the two products among untreated intravenous (IV) users. A survey was distributed to attendees at a Helsinki needle exchange program over 2-weeks in April, 2005, At least 30% were returned anonymously. Survey variables included: years of prior IV opioid abuse, years of buprenorphine abuse, frequency, dosage, route of administration and reasons for use, concomitant IV abuse of other substances and amount paid on the street for both buprenorphine and buprenorphine+naloxone. Buprenorphine was the most frequently used IV drug for 73% of the respondents. More than 75% said they used IV buprenorphine to self-treat addiction or withdrawal. Most (68%) had tried the buprenorphine+naloxone combination IV, but 80% said they had a "bad" experience. Its street price was less than half that of buprenorphine alone. The buprenorphine+naloxone combination appears to be a feasible tool, along with easier access to addiction treatment, for decreasing IV abuse of buprenorphine.
PubMed ID
17055191 View in PubMed
Less detail

Abuse of codeine separated from over-the-counter drugs containing acetylsalicylic acid and codeine.

https://arctichealth.org/en/permalink/ahliterature11779
Source
Int J Legal Med. 1993;105(5):279-81
Publication Type
Article
Date
1993
Author
S. Jensen
A C Hansen
Author Affiliation
Department of Forensic Pathology, Aarhus University, Risskov, Denmark.
Source
Int J Legal Med. 1993;105(5):279-81
Date
1993
Language
English
Publication Type
Article
Keywords
Aspirin - chemistry
Codeine - chemistry
Denmark
Drug Combinations
Drugs, Non-Prescription - chemistry
Humans
Substance Abuse Detection
Substance-Related Disorders - etiology
Abstract
In Denmark a new trend concerning the abuse of codeine has been observed. Danish drug abusers have discovered that codeine is easily separated from certain drugs containing acetylsalicylic acid and codeine. When separated the codeine can be used either orally or intravenously. Three different drugs combining acetylsalicylic acid and codeine are available in Denmark, but codeine is only easily separable from one of these. Applying the same procedure to the two other drugs produces unpredictable or unfavourable ratios of codeine to acetylsalicylic acid. In several countries, however, similar drugs combining acetylsalicylic acid and codeine are available. It is not possible from a list of constituents to predict how easily codeine can be separated from a particular drug. Therefore it is strongly recommended that relevant drugs are tested at local forensic laboratories. In case codeine is found to be very easily separated from a product appropriate action should be taken.
PubMed ID
8471545 View in PubMed
Less detail

[A calendar of prophylactic inoculations in wide practical use]

https://arctichealth.org/en/permalink/ahliterature38630
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Jan;(1):37-41
Publication Type
Article
Date
Jan-1988
Author
L M Chudnaia
A B Shekhter
L S Krasiuk
V G Oksiiuk
B N Fastovskaia
Source
Zh Mikrobiol Epidemiol Immunobiol. 1988 Jan;(1):37-41
Date
Jan-1988
Language
Russian
Publication Type
Article
Keywords
Antibody formation
Child
Child, Preschool
Comparative Study
Diphtheria Toxoid - immunology
Diphtheria-Tetanus-Pertussis Vaccine
Drug Combinations - immunology
English Abstract
Humans
Immunization Schedule
Immunization, Secondary
Infant
Measles Vaccine - immunology
Mumps Vaccine - immunology
Pertussis Vaccine - immunology
Poliovirus Vaccine, Inactivated - immunology
Rural Population
Tetanus Toxoid - immunology
Time Factors
Ukraine
Urban Population
Vaccination
Abstract
The validity of immunizations, made in due time in children aged up to 7 years in accordance with the approved immunization schedule, is analyzed in this work. The content of antibodies to diphtheria, tetanus and poliomyelitis antigens in children immunized in accordance with the old and new schedules has been studied. This study has revealed that the injection of adsorbed DPT vaccine to children aged 3-4 months induces fully valid immune response to all antigens under study. The level of measles and parotitis antibodies after the injections of measles and parotitis vaccines, introduced separately and simultaneously, has been measured. The simultaneous administration of these preparations did not decrease the levels of immunity to parotitis and measles.
PubMed ID
3259058 View in PubMed
Less detail

Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden.

https://arctichealth.org/en/permalink/ahliterature63498
Source
J Intern Med. 2003 Aug;254(2):176-83
Publication Type
Article
Date
Aug-2003
Author
C. Andersson
E. Innala
T. Bäckström
Author Affiliation
Department of Family Medicine, University Hospital, Umeå, Sweden. christer.andersson@fammed.umu.se
Source
J Intern Med. 2003 Aug;254(2):176-83
Date
Aug-2003
Language
English
Publication Type
Article
Keywords
Abortion, Spontaneous - etiology
Adolescent
Adult
Aged
Aged, 80 and over
Contraceptive Agents - therapeutic use
Contraceptives, Oral - therapeutic use
Drug Combinations
Estradiol - therapeutic use
Female
Hormone Replacement Therapy - methods
Humans
Menopause - physiology
Middle Aged
Porphyria, Acute Intermittent - complications - drug therapy - epidemiology
Pregnancy
Progesterone - therapeutic use
Retrospective Studies
Sweden - epidemiology
Vagina - drug effects
Abstract
OBJECTIVE: To describe the clinical expression of acute intermittent porphyria (AIP) in women, their use of exogenous sex hormones, and the effects on AIP. DESIGN: A retrospective population-based study. SUBJECTS: All women aged > or =18 years (n = 190) with DNA-diagnosed AIP in northern Sweden. RESULTS: A total of 166 women (87%) participated; 91 (55%) had manifest AIP. Severe attacks were reported by 82%; 39% reported recurrent premenstrual AIP attacks and 22% reported chronic AIP symptoms. Oral hormonal contraceptives had been used by 58% of all these women and by 50 with manifest AIP (57%). Twelve women (24%) associated oral contraceptives as precipitating AIP attacks; in nine cases their first attack. One woman experienced relief from AIP symptoms. On commencing their treatment, 72% of the women with manifest AIP had not yet suffered their first attack. Twenty-two women (25%) aged > or =45 years had used hormonal replacement therapy (HRT) at menopause to remedy climacteric symptoms (the percutaneous route was most frequently used); no AIP attack was precipitated. HRT to remedy vaginal dryness was used by 26 women (28%) aged > or =45 years without triggering an AIP attack. Miscarriages were more frequent in women with manifest AIP (50%) than in the latent group (30%, P = 0.014). CONCLUSIONS: About half of the women with AIP had used oral hormonal contraceptives. As 25% of women with manifest AIP reported attacks associated with such drugs, caution must still be recommended. Menopausal HRT only rarely affected the disorder. Miscarriage was more common amongst women with manifest AIP.
PubMed ID
12859699 View in PubMed
Less detail

[A cytomorphological basis for the correction of radiation-induced immunodeficiencies and hematopoietic depression using thymus and bone marrow peptides]

https://arctichealth.org/en/permalink/ahliterature46586
Source
Arkh Patol. 1993 Mar-Apr;55(2):50-3
Publication Type
Article
Author
O K Khmel'nitskii
I I Grintsevich
V A Kotov
S V Seryi
Source
Arkh Patol. 1993 Mar-Apr;55(2):50-3
Language
Russian
Publication Type
Article
Keywords
Accidents, Radiation
Adjuvants, Immunologic - therapeutic use
Adolescent
Adult
Animals
Comparative Study
Drug Combinations
Drug Evaluation
Drug Evaluation, Preclinical
English Abstract
Female
Guinea Pigs
Hematopoiesis - drug effects - radiation effects
Humans
Immunologic Deficiency Syndromes - drug therapy - etiology - pathology
Male
Middle Aged
Peptides - therapeutic use
Power Plants
Radiation Injuries - complications - drug therapy - pathology
Radiation Injuries, Experimental - complications - drug therapy - pathology
Thymus Hormones - therapeutic use
Ukraine
Abstract
The correction of radiation-induced immunodeficiency and hematopoiesis depression in clinical setting (100 patients) and in experiments (160 animals) by peptide preparations of the thymus and bone marrow (thymalin, hemalin, thymogemine and synthetic thymalin analog thymogen) has been studied. Administration of the bone marrow and thymus recovery of damage to the thymus, bone marrow, spleen and lymph nodes, improved the function of circulating neutrophilic granulocytes. Thymalin was able to compensate for immune disturbances and reduce manifestations of asthenia.
PubMed ID
7980063 View in PubMed
Less detail

Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study.

https://arctichealth.org/en/permalink/ahliterature9564
Source
Can Respir J. 2003 Nov-Dec;10(8):427-34
Publication Type
Article
Author
J Mark FitzGerald
Malcolm R Sears
Louis-Philippe Boulet
Allan B Becker
Andrew R McIvor
Pierre Ernst
Natasha M Smiljanic-Georgijev
Joanna S M Lee
Author Affiliation
The University of British Columbia, Vancouver, Canada. markj@interchange.ubc.ca
Source
Can Respir J. 2003 Nov-Dec;10(8):427-34
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adrenal Cortex Hormones - administration & dosage - therapeutic use
Adult
Asthma - drug therapy
Bronchodilator Agents - administration & dosage - therapeutic use
Budesonide - administration & dosage - therapeutic use
Canada
Child
Costs and Cost Analysis
Drug Administration Schedule
Drug Combinations
Ethanolamines - administration & dosage - therapeutic use
Female
Humans
Male
Research Support, Non-U.S. Gov't
Time Factors
Abstract
BACKGROUND: Adjustable maintenance dosing with budesonide/formoterol in a single inhaler (Symbicort, AstraZeneca, Lund, Sweden) may provide a convenient means of maintaining asthma control with the minimum effective medication level. OBJECTIVES: To compare adjustable and fixed maintenance dosing regimens of budesonide/formoterol in asthma. METHODS: This was an open-label, randomized, parallel-group, multicentre, Canadian study of asthma patients (aged 12 years or older, postbronchodilator forced expiratory volume in 1 s 70% or greater of predicted normal). Following a one-month run-in on budesonide/formoterol (100/6 mg or 200/6 mg metered doses, two inhalations twice daily), 995 patients were randomly assigned either to continue on this fixed dosing regimen or to receive budesonide/formoterol adjustable dosing (step down to one inhalation twice daily if symptoms were controlled or temporarily step up to four inhalations twice daily for seven or 14 days if asthma worsened). The primary efficacy variable was the occurrence of exacerbations (requiring oral or inhaled corticosteroids, emergency department treatment, serious adverse events or added maintenance therapy because of asthma). RESULTS: With adjustable dosing, significantly fewer patients experienced exacerbations compared with fixed dosing (4.0% versus 8.9%, P=0.002; number needed to treat=21 [95% CI 13 to 59]). Patients required 36% fewer overall doses of budesonide/formoterol (2.5 versus 3.9 inhalations/day, P
PubMed ID
14679407 View in PubMed
Less detail

[Adverse effects following sulfamethoxazole and trimethoprim. Review and 2 case reports]

https://arctichealth.org/en/permalink/ahliterature65948
Source
Ugeskr Laeger. 1979 Mar 12;141(11):709-11
Publication Type
Article
Date
Mar-12-1979

[Adverse effects of treatment with sulfamethoxazole and trimethoprim. Report to the Adverse Drug Reaction Committee of the National Board of Health and Welfare]

https://arctichealth.org/en/permalink/ahliterature57073
Source
Ugeskr Laeger. 1977 Jan 31;139(5):284-5
Publication Type
Article
Date
Jan-31-1977

417 records – page 1 of 42.